Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
PR NewswireJul 30, 2024
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically significant reduction (p<0.0001), which was sustained at week 52 (p<0.0001) -- -- Obicetrapib lowered LDL-C by 36.3% at week 12 and by 41.5% at week 52, compared to placebo -- -- Obicetrapib was well-tolerated; safety results comparable to placebo-- FLORENCE, Italy, July 29, 2024 /PRNewswire/ -- Menarini Group today annou